MENY

Gällande vårdprogram livmoderhals och vagina

Fastställt av Regionala cancercentrum i samverkan 2017-06-14

20. Referenser

1.SoS dödsorsaker 2013.

2.SoS cancerincidens i Sverige 2013, 2014.

3.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on day/month/year.

4.Gynekologisk cellprovskontroll, Socialstyrelsen rapport 1998:15 ISBN 91-7201-290-0 

5.SFOG ARG rapp 63 2010.

6.NORDCAN 2013: cancerstatistik cervixcancer.

7.Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. Journal of the National Cancer Institute. 2008;100(9):622-9.

8.Darlin L, Borgfeldt C, Widen E, Kannisto P. Elderly women above screening age diagnosed with cervical cancer have a worse prognosis. Anticancer research. 2014;34(9):5147-51.

9.Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, et al. Screening and cervical cancer cure: population based cohort study. Bmj. 2012;344:e900.

10.Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.

11.de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology. 2010;11(11):1048-56.

12.Castellsague X, Drudis T, Canadas MP, Gonce A, Ros R, Perez JM, et al. Human Papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. BMC infectious diseases. 2009;9:74.

13.Syrjanen K, Hakama M, Saarikoski S, Vayrynen M, Yliskoski M, Syrjanen S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sexually transmitted diseases. 1990;17(1):15-9.

14.Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. The Journal of infectious diseases. 1995;171(4):1026-30.

15.Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831-6.

16.Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstetrics and gynecology. 2002;100(5 Pt 1):965-71.

17.International Collaboration of Epidemiological Studies of Cervical C, Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. International journal of cancer Journal international du cancer. 2006;118(6):1481-95.

18.Silins I, Ryd W, Strand A, Wadell G, Tornberg S, Hansson BG, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. International journal of cancer Journal international du cancer. 2005;116(1):110-5.

19.International Collaboration of Epidemiological Studies of Cervical C, Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609-21.

20.Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res. 2002;89(2):191-9.

21.Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. Journal of the National Cancer Institute Monographs. 2003(31):14-9.

22.Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. The New England journal of medicine. 2006;354(25):2645-54.

23.Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an identification technique. British journal of cancer. 1989;60(1):132-41.

24.Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1993;12(2):186-92.

25.Nasiell K, Nasiell M, Vaclavinkova V. Behavior of moderate cervical dysplasia during long-term follow-up. Obstetrics and gynecology. 1983;61(5):609-14.

26.van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. British journal of cancer. 1991;64(3):559-65.

27.McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstetrics and gynecology. 1984;64(4):451-8.

28.McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. The Lancet Oncology. 2008;9(5):425-34.

29.Palefsky J. Human papillomavirus-related disease in people with HIV. Current opinion in HIV and AIDS. 2009;4(1):52-6.

30.Wright TC, Jr., Koulos J, Schnoll F, Swanbeck J, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecologic oncology. 1994;55(2):253-8.

31.Strander B, Hallgren J, Sparen P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. Bmj. 2014;348:f7361.

32.Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32.

33.Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd ML, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. International journal of cancer Journal international du cancer. 2014;134(9):2223-30.

34.Group FIS. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. The Journal of infectious diseases. 2007;196(10):1438-46.

35.Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England journal of medicine. 2007;356(19):1915-27.

36.Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. British journal of cancer. 2011;105(1):28-37.

37.Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-14.

38.Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology. 2012;13(1):89-99.

39.Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. The New England journal of medicine. 2015;372(8):711-23.

40.Socialstyrelsen 2008 Background to a Human Papillomavirus Vaccination Program in Sweden.

41.Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. Journal of the National Cancer Institute. 2013;105(7):469-74.

42.Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, et al. Therapy of human papillomavirus-related disease. Vaccine. 2012;30 Suppl 5:F71-82.

43.Denny L, Quinn M, Hacker N. FIGO Cancer Report 2012. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2012;119 Suppl 2:S89.

44.Heard I. Prevention of cervical cancer in women with HIV. Current opinion in HIV and AIDS. 2009;4(1):68-73.

45.Zand B, Euscher ED, Soliman PT, Schmeler KM, Coleman RL, Frumovitz M, et al. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecologic oncology. 2010;119(3):422-5.

46.Narayan K. Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2005;15(4):573-82.

47.Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic oncology. 1990;38(3):352-7.

48.Lagasse LD, Creasman WT, Shingleton HM, Ford JH, Blessing JA. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecologic oncology. 1980;9(1):90-8.

49.Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009;105(2):107-8.

50.Kim WY, Chang SJ, Chang KH, Yoo SC, Lee EJ, Ryu HS. Reliability of magnetic resonance imaging for bladder or rectum invasion in cervical cancer. The Journal of reproductive medicine. 2011;56(11-12):485-90.

51.Sala E, Wakely S, Senior E, Lomas D. MRI of malignant neoplasms of the uterine corpus and cervix. AJR American journal of roentgenology. 2007;188(6):1577-87.

52.Bipat S, Glas AS, van der Velden J, Zwinderman AH, Bossuyt PM, Stoker J. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecologic oncology. 2003;91(1):59-66.

53.Young P, Daniel B, Sommer G, Kim B, Herfkens R. Intravaginal gel for staging of female pelvic cancers--preliminary report of safety, distention, and gel-mucosal contrast during magnetic resonance examination. Journal of computer assisted tomography. 2012;36(2):253-6.

54.Testa AC, Di Legge A, De Blasis I, Moruzzi MC, Bonatti M, Collarino A, et al. Imaging techniques for the evaluation of cervical cancer. Best practice & research Clinical obstetrics & gynaecology. 2014;28(5):741-68.

55.Balleyguier C, Sala E, Da Cunha T, Bergman A, Brkljacic B, Danza F, et al. Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. European radiology. 2011;21(5):1102-10.

56.Choi HJ, Ju W, Myung SK, Kim Y. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer science. 2010;101(6):1471-9.

57.Narayan K, Fisher RJ, Bernshaw D. Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by magnetic resonance imaging and treated with curative intent. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(3):525-33.

58.Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola MA, et al. Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. Gynecologic oncology. 2009;112(1):95-103.

59.de Boer P, Adam JA, Buist MR, van de Vijver MJ, Rasch CR, Stoker J, et al. Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy. European journal of radiology. 2013;82(9):e422-8.

60.Thomeer MG, Gerestein C, Spronk S, van Doorn HC, van der Ham E, Hunink MG. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. European radiology. 2013;23(7):2005-18.

61.Burghardt E, Hofmann HM, Ebner F, Haas J, Tamussino K, Justich E. Magnetic resonance imaging in cervical cancer: a basis for objective classification. Gynecologic oncology. 1989;33(1):61-7.

62.Hricak H, Lacey CG, Sandles LG, Chang YC, Winkler ML, Stern JL. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology. 1988;166(3):623-31.

63.Kim SH, Choi BI, Lee HP, Kang SB, Choi YM, Han MC, et al. Uterine cervical carcinoma: comparison of CT and MR findings. Radiology. 1990;175(1):45-51.

64.Lien HH, Blomlie V, Iversen T, Trope C, Sundfor K, Abeler VM. Clinical stage I carcinoma of the cervix. Value of MR imaging in determining invasion into the parametrium. Acta radiologica. 1993;34(2):130-2.

65.Rubens D, Thornbury JR, Angel C, Stoler MH, Weiss SL, Lerner RM, et al. Stage IB cervical carcinoma: comparison of clinical, MR, and pathologic staging. AJR American journal of roentgenology. 1988;150(1):135-8.

66.Sironi S, Belloni C, Taccagni GL, DelMaschio A. Carcinoma of the cervix: value of MR imaging in detecting parametrial involvement. AJR American journal of roentgenology. 1991;156(4):753-6.

67.Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstetrics and gynecology. 1995;86(1):43-50.

68.Togashi K, Nishimura K, Sagoh T, Minami S, Noma S, Fujisawa I, et al. Carcinoma of the cervix: staging with MR imaging. Radiology. 1989;171(1):245-51.

69.Fischerova D, Cibula D, Stenhova H, Vondrichova H, Calda P, Zikan M, et al. Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(4):766-72.

70.Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(36):9329-37.

71.Choi SH, Kim SH, Choi HJ, Park BK, Lee HJ. Preoperative magnetic resonance imaging staging of uterine cervical carcinoma: results of prospective study. Journal of computer assisted tomography. 2004;28(5):620-7.

72.Kim SH, Choi BI, Han JK, Kim HD, Lee HP, Kang SB, et al. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. Journal of computer assisted tomography. 1993;17(4):633-40.

73.Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology. 2013;266(3):717-40.

74.Stenstedt K, Hellstrom AC, Fridsten S, Blomqvist L. Impact of MRI in the management and staging of cancer of the uterine cervix. Acta oncologica. 2011;50(3):420-6.

75.Thoeny HC, Forstner R, De Keyzer F. Genitourinary applications of diffusion-weighted MR imaging in the pelvis. Radiology. 2012;263(2):326-42.

76.Sala E, Rockall A, Rangarajan D, Kubik-Huch RA. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis. European journal of radiology. 2010;76(3):367-85.

77.Barwick TD, Taylor A, Rockall A. Functional imaging to predict tumor response in locally advanced cervical cancer. Current oncology reports. 2013;15(6):549-58.

78.Testa AC, Ludovisi M, Manfredi R, Zannoni G, Gui B, Basso D, et al. Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancer. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2009;34(3):335-44.

79.Yang WT, Walkden SB, Ho S, Cheung TH, Lam SK, Teo J, et al. Transrectal ultrasound in the evaluation of cervical carcinoma and comparison with spiral computed tomography and magnetic resonance imaging. The British journal of radiology. 1996;69(823):610-6.

80.Epstein E, Testa A, Gaurilcikas A, Di Legge A, Ameye L, Atstupenaite V, et al. Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound - a European multicenter trial. Gynecologic oncology. 2013;128(3):449-53.

81.Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen WK, Paulino AC, et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. International journal of radiation oncology, biology, physics. 2002;52(1):14-22.

82.Epstein E, Di Legge A, Masback A, Lindqvist PG, Kannisto P, Testa AC. Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2010;36(4):512-6.

83.Cobby M, Browning J, Jones A, Whipp E, Goddard P. Magnetic resonance imaging, computed tomography and endosonography in the local staging of carcinoma of the cervix. The British journal of radiology. 1990;63(753):673-9.

84.Innocenti P, Pulli F, Savino L, Nicolucci A, Pandimiglio A, Menchi I, et al. Staging of cervical cancer: reliability of transrectal US. Radiology. 1992;185(1):201-5.

85.Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecologic oncology. 2005;97(1):183-91.

86.Selman TJ, Mann C, Zamora J, Appleyard TL, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2008;178(7):855-62.

87.Salem A, Salem AF, Al-Ibraheem A, Lataifeh I, Almousa A, Jaradat I. Evidence for the use PET for radiation therapy planning in patients with cervical cancer: a systematic review. Hematology/oncology and stem cell therapy. 2011;4(4):173-81.

88.Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. International journal of radiation oncology, biology, physics. 2010;77(4):1085-91.

89.Zhao Q, Feng Y, Mao X, Qie M. Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography or PET-computed tomography in cervical cancer: a meta-analysis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(7):1184-90.

90.Bjurberg M, Kjellen E, Ohlsson T, Bendahl PO, Brun E. Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(9):1600-5.

91.Chung HH, Lee I, Kim HS, Kim JW, Park NH, Song YS, et al. Prognostic value of preoperative metabolic tumor volume measured by (1)(8)F-FDG PET/CT and MRI in patients with endometrial cancer. Gynecologic oncology. 2013;130(3):446-51.

92.Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. International journal of radiation oncology, biology, physics. 2012;83(1):185-90.

93.Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nuclear medicine communications. 2014;35(2):144-50.

94.Meads C, Auguste P, Davenport C, Malysiak S, Sundar S, Kowalska M, et al. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling. Health technology assessment. 2013;17(12):1-323.

95.Xiao Y, Wei J, Zhang Y, Xiong W. Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis. Archives of medical science : AMS. 2014;10(2):222-31.

96.Fischerova D. Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: a review. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2011;38(3):246-66.

97.Hwang L, Bailey A, Lea J, Albuquerque K. Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management. Future oncology. 2015;11(2):309-22.

98.Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009;105(2):103-4.

99.International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 7th ed. Sorbin LH, Gospodarowicz MK, Wittekind Ch, eds. New York; Wiley; 2009.

100.Beller U, Benedet JL, Creasman WT, Ngan HY, Quinn MA, Maisonneuve P, et al. Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2006;95 Suppl 1:S29-42.

101.WHO Classification of Tumours of Female Reproductive Organs 4th edition 2014.  Ed. Kurman R. ISBN 978-92-832-2435-8.

102.Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nature reviews Cancer. 2007;7(1):11-22.

103.Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Archives of pathology & laboratory medicine. 2012;136(10):1266-97.

104.Horvath LE, Yordan E, Malhotra D, Leyva I, Bortel K, Schalk D, et al. Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. Journal of oncology practice / American Society of Clinical Oncology. 2010;6(6):e21-6.

105.Greer HO, Frederick PJ, Falls NM, Tapley EB, Samples KL, Kimball KJ, et al. Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(8):1321-5.

106.Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year prospective survey. Journal of cancer education : the official journal of the American Association for Cancer Education. 2008;23(4):235-7.

107.Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2006;95 Suppl 1:S43-103.

108.Polterauer S, Grimm C, Hofstetter G, Concin N, Natter C, Sturdza A, et al. Nomogram prediction for overall survival of patients diagnosed with cervical cancer. British journal of cancer. 2012;107(6):918-24.

109.Inoue T, Okumura M. Prognostic significance of parametrial extension in patients with cervical carcinoma Stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation. Cancer. 1984;54(8):1714-9.

110.Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18(8):1606-13.

111.National Comprehensive Cancer network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms. V.1.2010. www.nccn.org.

112.Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012;23 Suppl 7:vii27-32.

113.Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. International journal of clinical oncology. 2007;12(3):165-75.

114.Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2000;10(4):305-12.

115.Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecologic oncology. 2007;107(2):310-5.

116.Horn LC, Bilek K, Fischer U, Einenkel J, Hentschel B. A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer. Gynecologic oncology. 2014;134(1):42-6.

117.Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer. 1990;65(9):1923-7.

118.Aoki Y, Sasaki M, Watanabe M, Sato T, Tsuneki I, Aida H, et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Gynecologic oncology. 2000;77(2):305-9.

119.Macdonald OK, Chen J, Dodson M, Lee CM, Gaffney DK. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. American journal of clinical oncology. 2009;32(4):411-6.

120.Kato T, Watari H, Takeda M, Hosaka M, Mitamura T, Kobayashi N, et al. Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy. Journal of gynecologic oncology. 2013;24(3):222-8.

121.Morice P, Castaigne D, Pautier P, Rey A, Haie-Meder C, Leblanc M, et al. Interest of pelvic and paraaortic lymphadenectomy in patients with stage IB and II cervical carcinoma. Gynecologic oncology. 1999;73(1):106-10.

122.Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer. 1999;85(7):1547-54.

123.Horn LC, Hentschel B, Galle D, Bilek K. Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri. Gynecologic oncology. 2008;108(1):63-7.

124.Singh P, Tripcony L, Nicklin J. Analysis of prognostic variables, development of predictive models, and stratification of risk groups in surgically treated FIGO early-stage (IA-IIA) carcinoma cervix. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012;22(1):115-22.

125.Milam MR, Frumovitz M, dos Reis R, Broaddus RR, Bassett RL, Jr., Ramirez PT. Preoperative lymph-vascular space invasion is associated with nodal metastases in women with early-stage cervical cancer. Gynecologic oncology. 2007;106(1):12-5.

126.Benedet JL, Anderson GH. Stage IA carcinoma of the cervix revisited. Obstetrics and gynecology. 1996;87(6):1052-9.

127.Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecologic oncology. 2004;92(2):525-9.

128.Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, et al. How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecologic oncology. 2002;84(1):145-9.

129.Drescher CW, Hopkins MP, Roberts JA. Comparison of the pattern of metastatic spread of squamous cell cancer and adenocarcinoma of the uterine cervix. Gynecologic oncology. 1989;33(3):340-3.

130.Shingleton HM, Bell MC, Fremgen A, Chmiel JS, Russell AH, Jones WB, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer. 1995;76(10 Suppl):1948-55.

131.Grisaru D, Covens A, Chapman B, Shaw P, Colgan T, Murphy J, et al. Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer. 2001;92(12):2999-3004.

132.Winer I, Alvarado-Cabrero I, Hassan O, Ahmed QF, Alosh B, Bandyopadhyay S, et al. The prognostic significance of histologic type in early stage cervical cancer - A multi-institutional study. Gynecologic oncology. 2015;137(3):474-8.

133.Murakami I, Fujii T, Kameyama K, Iwata T, Saito M, Kubushiro K, et al. Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix. Journal of gynecologic oncology. 2012;23(3):153-8.

134.Lee JY, Lee C, Hahn S, Kim MA, Kim HS, Chung HH, et al. Prognosis of adenosquamous carcinoma compared with adenocarcinoma in uterine cervical cancer: a systematic review and meta-analysis of observational studies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(2):289-94.

135.Burghardt E, Pickel H. Local spread and lymph node involvement in cervical cancer. Obstetrics and gynecology. 1978;52(2):138-45.

136.Horn LC, Meinel A, Handzel R, Einenkel J. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Annals of diagnostic pathology. 2007;11(4):297-311.

137.Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(6):982-9.

138.Maneo A, Sideri M, Scambia G, Boveri S, Dell'anna T, Villa M, et al. Simple conization and lymphadenectomy for the conservative treatment of stage IB1 cervical cancer. An Italian experience. Gynecologic oncology. 2011;123(3):557-60.

139.McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, et al. The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer. Gynecologic oncology. 2013;128(1):44-8.

140.Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecologic oncology. 1999;73(2):177-83.

141.Billingsley CC, Kohler MF, Creasman WT, Madory JE, Young JL. A case of parametrial lymph node involvement in stage IA2 squamous cell carcinoma of the cervix treated with radical hysterectomy and a review of the literature: a case report. Journal of lower genital tract disease. 2012;16(2):145-8.

142.Peccatori FA, Azim HA, Jr., Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24 Suppl 6:vi160-70.

143.Wright JD, Grigsby PW, Brooks R, Powell MA, Gibb RK, Gao F, et al. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer. 2007;110(6):1281-6.

144.Kucukmetin A, Biliatis I, Naik R, Bryant A. Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer. The Cochrane database of systematic reviews. 2013;10:CD006651.

145.Naik R, Jackson KS, Lopes A, Cross P, Henry JA. Laparoscopic assisted radical vaginal hysterectomy versus radical abdominal hysterectomy--a randomised phase II trial: perioperative outcomes and surgicopathological measurements. BJOG : an international journal of obstetrics and gynaecology. 2010;117(6):746-51.

146.Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, et al. A case-control study of robot-assisted type III radical hysterectomy with pelvic lymph node dissection compared with open radical hysterectomy. American journal of obstetrics and gynecology. 2008;199(4):357 e1-7.

147.Soliman PT, Frumovitz M, Sun CC, Dos Reis R, Schmeler KM, Nick AM, et al. Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecologic oncology. 2011;123(2):333-6.

148.Reynisson P, Persson J. Hospital costs for robot-assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy. Gynecologic oncology. 2013;130(1):95-9.

149.Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, et al. Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer. Gynecologic oncology. 2012;127(1):11-7.

150.Cantrell LA, Mendivil A, Gehrig PA, Boggess JF. Survival outcomes for women undergoing type III robotic radical hysterectomy for cervical cancer: a 3-year experience. Gynecologic oncology. 2010;117(2):260-5.

151.Cao DY, Yang JX, Wu XH, Chen YL, Li L, Liu KJ, et al. Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China. British journal of cancer. 2013;109(11):2778-82.

152.van Meurs H, Visser O, Buist MR, Ten Kate FJ, van der Velden J. Frequency of pelvic lymph node metastases and parametrial involvement in stage IA2 cervical cancer: a population-based study and literature review. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(1):21-6.

153.Bisseling KC, Bekkers RL, Rome RM, Quinn MA. Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. Gynecologic oncology. 2007;107(3):424-30.

154.Hockel M, Horn LC, Manthey N, Braumann UD, Wolf U, Teichmann G, et al. Resection of the embryologically defined uterovaginal (Mullerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis. The Lancet Oncology. 2009;10(7):683-92.

155.Kimmig R, Aktas B, Buderath P, Wimberger P, Iannaccone A, Heubner M. Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Hockel translated to robotic surgery. World journal of surgical oncology. 2013;11:198.

156.Cibula D, Velechovska P, Slama J, Fischerova D, Pinkavova I, Pavlista D, et al. Late morbidity following nerve-sparing radical hysterectomy. Gynecologic oncology. 2010;116(3):506-11.

157.Maas CP, Trimbos JB, DeRuiter MC, van de Velde CJ, Kenter GG. Nerve sparing radical hysterectomy: latest developments and historical perspective. Critical reviews in oncology/hematology. 2003;48(3):271-9.

158.Butler-Manuel SA, Buttery LD, A'Hern RP, Polak JM, Barton DP. Pelvic nerve plexus trauma at radical and simple hysterectomy: a quantitative study of nerve types in the uterine supporting ligaments. J Soc Gynecol Investig. 2002;9(1):47-56.

159.Pieterse QD, Kenter GG, Maas CP, de Kroon CD, Creutzberg CL, Trimbos JB, et al. Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(9):1717-25.

160.Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y, et al. Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. British journal of cancer. 2009;100(9):1400-5.

161.Shimada M, Kigawa J, Nishimura R, Yamaguchi S, Kuzuya K, Nakanishi T, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecologic oncology. 2006;101(2):234-7.

162.Omar T, Marie P. Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review. Gynecologic oncology. 2015;136(2):384-8.

163.Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstetrics and gynecology. 2009;113(5):1027-37.

164.Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ, 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. The Lancet Oncology. 2006;7(10):821-8.

165.Falcone T, Attaran M, Bedaiwy MA, Goldberg JM. Ovarian function preservation in the cancer patient. Fertility and sterility. 2004;81(2):243-57.

166.Pahisa J, Martinez-Roman S, Martinez-Zamora MA, Torne A, Caparros X, Sanjuan A, et al. Laparoscopic ovarian transposition in patients with early cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(3):584-9.

167.Feeney DD, Moore DH, Look KY, Stehman FB, Sutton GP. The fate of the ovaries after radical hysterectomy and ovarian transposition. Gynecologic oncology. 1995;56(1):3-7.

168.Querleu D, Morrow CP. Classification of radical hysterectomy. Gynecologic oncology. 2009;115(2):314-5; author reply 5-6.

169.Pieterse QD, Kenter GG, Gaarenstroom KN, Peters AA, Willems SM, Fleuren GJ, et al. The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2007;33(2):216-21.

170.Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cardenas-Rebollo JM, et al. Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(9):1647-54.

171.Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535-40.

172.Barter JF, Soong SJ, Shingleton HM, Hatch KD, Orr JW, Jr. Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecologic oncology. 1989;32(3):292-6.

173.Chai Y, Wang T, Wang J, Yang Y, Gao Y, Gao J, et al. Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer. BMC cancer. 2014;14:63.

174.Rogers L, Siu SS, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer. The Cochrane database of systematic reviews. 2012;5:CD007583.

175.Richard SD, Krivak TC, Castleberry A, Beriwal S, Kelley JL, 3rd, Edwards RP, et al. Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecologic oncology. 2008;109(1):43-8.

176.Leath CA, 3rd, Straughn JM, Jr., Estes JM, Kirby TO, Bhoola SM, Barnes MN, 3rd, et al. The impact of aborted radical hysterectomy in patients with cervical carcinoma. Gynecologic oncology. 2004;95(1):204-7.

177.Marnitz S, Kohler C, Affonso RJ, Schneider A, Chiantera V, Tsounoda A, et al. Validity of laparoscopic staging to avoid adjuvant chemoradiation following radical surgery in patients with early cervical cancer. Oncology. 2012;83(6):346-53.

178.Dargent D, Mathevet P. Schauta's vaginal hysterectomy combined with laparoscopic lymphadenectomy. Bailliere's clinical obstetrics and gynaecology. 1995;9(4):691-705.

179.Smith JR, Boyle DC, Corless DJ, Ungar L, Lawson AD, Del Priore G, et al. Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma. British journal of obstetrics and gynaecology. 1997;104(10):1196-200.

180.Abu-Rustum NR, Sonoda Y, Black D, Levine DA, Chi DS, Barakat RR. Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecologic oncology. 2006;103(3):807-13.

181.Sonoda Y, Abu-Rustum NR, Gemignani ML, Chi DS, Brown CL, Poynor EA, et al. A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? Gynecologic oncology. 2004;95(3):534-8.

182.Dargent D, Franzosi F, Ansquer Y, Martin X, Mathevet P, Adeline P. [Extended trachelectomy relapse: plea for patient involvement in the medical decision]. Bulletin du cancer. 2002;89(12):1027-30.

183.Rob L, Skapa P, Robova H. Fertility-sparing surgery in patients with cervical cancer. The Lancet Oncology. 2011;12(2):192-200.

184.Lanowska M, Mangler M, Spek A, Grittner U, Hasenbein K, Chiantera V, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic lymphadenectomy: prospective study of 225 patients with early-stage cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(8):1458-64.

185.Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer. 2001;92(9):2471-83.

186.Singh N, Arif S. Histopathologic parameters of prognosis in cervical cancer--a review. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2004;14(5):741-50.

187.Beiner ME, Hauspy J, Rosen B, Murphy J, Laframboise S, Nofech-Mozes S, et al. Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: a matched case-control study. Gynecologic oncology. 2008;110(2):168-71.

188.Speiser D, Mangler M, Kohler C, Hasenbein K, Hertel H, Chiantera V, et al. Fertility outcome after radical vaginal trachelectomy: a prospective study of 212 patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(9):1635-9.

189.Speiser D, Kohler C, Schneider A, Mangler M. Radical vaginal trachelectomy: a fertility-preserving procedure in early cervical cancer in young women. Deutsches Arzteblatt international. 2013;110(17):289-95.

190.Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer treatment reports. 1987;71(10):941-4.

191.Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecologic oncology. 2011;121(2):290-7.

192.Plante M, Gregoire J, Renaud MC, Sebastianelli A, Grondin K, Noel P, et al. Simple vaginal trachelectomy in early-stage low-risk cervical cancer: a pilot study of 16 cases and review of the literature. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(5):916-22.

193.Trimbos JB, Franchi M, Zanaboni F, Velden J, Vergote I. 'State of the art' of radical hysterectomy; current practice in European oncology centres. European journal of cancer. 2004;40(3):375-8.

194.Frumovitz M, dos Reis R, Sun CC, Milam MR, Bevers MW, Brown J, et al. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstetrics and gynecology. 2007;110(1):96-102.

195.Kruijdenberg CB, van den Einden LC, Hendriks JC, Zusterzeel PL, Bekkers RL. Robot-assisted versus total laparoscopic radical hysterectomy in early cervical cancer, a review. Gynecologic oncology. 2011;120(3):334-9.

196.Montz FJ, Holschneider CH, Solh S, Schuricht LC, Monk BJ. Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings. Gynecologic oncology. 1994;53(1):114-20.

197.Cardosi RJ, Cox CS, Hoffman MS. Postoperative neuropathies after major pelvic surgery. Obstetrics and gynecology. 2002;100(2):240-4.

198.Persson J, Reynisson P, Borgfeldt C, Kannisto P, Lindahl B, Bossmar T. Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity data. Gynecologic oncology. 2009;113(2):185-90.

199.Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16(3):1130-9.

200.Barnes W, Waggoner S, Delgado G, Maher K, Potkul R, Barter J, et al. Manometric characterization of rectal dysfunction following radical hysterectomy. Gynecologic oncology. 1991;42(2):116-9.

201.Hur HC, Donnellan N, Mansuria S, Barber RE, Guido R, Lee T. Vaginal cuff dehiscence after different modes of hysterectomy. Obstetrics and gynecology. 2011;118(4):794-801.

202.Nick AM, Lange J, Frumovitz M, Soliman PT, Schmeler KM, Schlumbrecht MP, et al. Rate of vaginal cuff separation following laparoscopic or robotic hysterectomy. Gynecologic oncology. 2011;120(1):47-51.

203.Maggioni A, Minig L, Zanagnolo V, Peiretti M, Sanguineti F, Bocciolone L, et al. Robotic approach for cervical cancer: comparison with laparotomy: a case control study. Gynecologic oncology. 2009;115(1):60-4.

204.Achouri A, Huchon C, Bats AS, Bensaid C, Nos C, Lecuru F. Complications of lymphadenectomy for gynecologic cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2013;39(1):81-6.

205.Hareyama H, Hada K, Goto K, Watanabe S, Hakoyama M, Oku K, et al. Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies: a retrospective study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2015;25(4):751-7.

206.Fuller J, Guderian D, Kohler C, Schneider A, Wendt TG. Lymph edema of the lower extremities after lymphadenectomy and radiotherapy for cervical cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al]. 2008;184(4):206-11.

207.Kondo E, Tabata T, Shiozaki T, Motohashi T, Tanida K, Okugawa T, et al. Large or persistent lymphocyst increases the risk of lymphedema, lymphangitis, and deep vein thrombosis after retroperitoneal lymphadenectomy for gynecologic malignancy. Archives of gynecology and obstetrics. 2013;288(3):587-93.

208.Lecuru F, Mathevet P, Querleu D, Leblanc E, Morice P, Darai E, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(13):1686-91.

209.Roy M, Bouchard-Fortier G, Popa I, Gregoire J, Renaud MC, Tetu B, et al. Value of sentinel node mapping in cancer of the cervix. Gynecologic oncology. 2011;122(2):269-74.

210.Cibula D, Abu-Rustum NR, Dusek L, Zikan M, Zaal A, Sevcik L, et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecologic oncology. 2012;124(3):496-501.

211.Slama J, Dundr P, Dusek L, Cibula D. High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer. Gynecologic oncology. 2013;129(2):384-8.

212.Marnitz S, Kohler C, Muller M, Behrens K, Hasenbein K, Schneider A. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecologic oncology. 2006;103(3):1023-30.

213.Chiantera V, Rossi M, De Iaco P, Koehler C, Marnitz S, Ferrandina G, et al. Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(5):916-22.

214.Cetina L, Gonzalez-Enciso A, Cantu D, Coronel J, Perez-Montiel D, Hinojosa J, et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(8):2043-7.

215.Motton S, Houvenaeghel G, Delannes M, Querleu D, Soule-Tholy M, Hoff J, et al. Results of surgery after concurrent chemoradiotherapy in advanced cervical cancer: comparison of extended hysterectomy and extrafascial hysterectomy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(2):268-75.

216.Kupets R, Thomas GM, Covens A. Is there a role for pelvic lymph node debulking in advanced cervical cancer? Gynecologic oncology. 2002;87(2):163-70.

217.Lai CH, Huang KG, Hong JH, Lee CL, Chou HH, Chang TC, et al. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecologic oncology. 2003;89(1):160-7.

218.Gil-Moreno A, Franco-Camps S, Cabrera S, Perez-Benavente A, Martinez-Gomez X, Garcia A, et al. Pretherapeutic extraperitoneal laparoscopic staging of bulky or locally advanced cervical cancer. Annals of surgical oncology. 2011;18(2):482-9.

219.Cosin JA, Fowler JM, Chen MD, Paley PJ, Carson LF, Twiggs LB. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer. 1998;82(11):2241-8.

220.Marnitz S, Kohler C, Roth C, Fuller J, Hinkelbein W, Schneider A. Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer? Gynecologic oncology. 2005;99(3):536-44.

221.Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Management of occult invasive cervical cancer found after simple hysterectomy. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21(5):994-1000.

222.Munstedt K, von Georgi R, Zygmunt M, Misselwitz B, Stillger R, Kunzel W. Shortcomings and deficits in surgical treatment of gynecological cancers: a German problem only? Gynecologic oncology. 2002;86(3):337-43.

223.Narducci F, Merlot B, Bresson L, Katdare N, Le Tinier F, Cordoba A, et al. Occult invasive cervical cancer found after inadvertent simple hysterectomy: is the ideal management: systematic parametrectomy with or without radiotherapy or radiotherapy only? Annals of surgical oncology. 2015;22(4):1349-52.

224.Buda A, Pellegrino A, Vitobello D, Meroni MG, Recalcati D, Perego P. Total laparoscopic radical parametrectomy, partial colpectomy, and pelvic lymphadenectomy in patients with occult cervical cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009;107(1):73-6.

225.Leath CA, 3rd, Straughn JM, Bhoola SM, Partridge EE, Kilgore LC, Alvarez RD. The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy. Gynecologic oncology. 2004;92(1):215-9.

226.Hellstrom AC, Hellman K, Pettersson BF, Andersson S. Carcinoma of the cervical stump: fifty years of experience. Oncology reports. 2011;25(6):1651-4.

227.Hellstrom AC, Sigurjonson T, Pettersson F. Carcinoma of the cervical stump. The radiumhemmet series 1959-1987. Treatment and prognosis. Acta obstetricia et gynecologica Scandinavica. 2001;80(2):152-7.

228.Barillot I, Horiot JC, Cuisenier J, Pigneux J, Schraub S, Rozan R, et al. Carcinoma of the cervical stump: a review of 213 cases. European journal of cancer. 1993;29A(9):1231-6.

229.Hannoun-Levi JM, Peiffert D, Hoffstetter S, Luporsi E, Bey P, Pernot M. Carcinoma of the cervical stump: retrospective analysis of 77 cases. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1997;43(2):147-53.

230.Liang Z, Xu H, Chen Y, Li Y, Chang Q, Shi C. Laparoscopic radical trachelectomy or parametrectomy and pelvic and para-aortic lymphadenectomy for cervical or vaginal stump carcinoma: report of six cases. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16(4):1713-6.

231.Lee YS, Lee TH, Koo TB, Cho YL, Park I. Laparoscopic radical parametrectomy including paraaortic and pelvic lymphadenectomy in women after prior hysterectomy: three cases. Journal of laparoendoscopic & advanced surgical techniques Part A. 2003;13(2):123-6.

232.Kohler C, Tozzi R, Klemm P, Schneider A. "Schauta sine utero": technique and results of laparoscopic-vaginal radical parametrectomy. Gynecologic oncology. 2003;91(2):359-68.

233.Shah AN, Olah KS. Cervical stump carcinoma following subtotal hysterectomy. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2002;22(6):701.

234.Mendez LE, Penalver M, McCreath W, Bejarano P, Angioli R. Radical vaginal trachelectomy after supracervical hysterectomy. Gynecologic oncology. 2002;85(3):545-7.

235.Lee CL, Huang KG, Wang CJ, Yen CF, Soong YK. Radical laparoscopic surgery for carcinoma of the cervical stump. The Journal of the American Association of Gynecologic Laparoscopists. 2000;7(2):241-4.

236.Modarress M, Maghami FQ, Golnavaz M, Behtash N, Mousavi A, Khalili GR. Comparative study of chemoradiation and neoadjuvant chemotherapy effects before radical hysterectomy in stage IB-IIB bulky cervical cancer and with tumor diameter greater than 4 cm. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2005;15(3):483-8.

237.Lee JY, Kim YH, Kim MJ, Kim K, Chung HH, Park NH, et al. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy. Archives of gynecology and obstetrics. 2011;284(2):477-82.

238.Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. The Cochrane database of systematic reviews. 2012;12:CD007406.

239.Yamaguchi S, Fujiwara K, Sato S, Nagao S, Takehara K, Nishimura M, Shimada M, Kigawa J, Tanioka M (2014) Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advaned cervical cancer. Final results of a multicenter phase II study (Sankai gynecology study group 013), JCO 32:5supplement, Abstract 5526.

240.Landoni F, Sartori E, Maggino T, Zola P, Zanagnolo V, Cosio S, et al. Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecologic oncology. 2014;132(3):611-7.

241.Vair B, Altman AD, Nelson G. Time to surgery and the risk of cancer progression in patients with gynaecologic cancers of the lower genital tract. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2015;37(4):338-44.

242.Mabuchi S, Okazawa M, Isohashi F, Matsuo K, Ohta Y, Suzuki O, et al. Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer. Gynecologic oncology. 2011;123(2):241-7.

243.Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(3):320-43.

244.Withers HR, Suwinski R. Radiation dose response for subclinical metastases. Seminars in radiation oncology. 1998;8(3):224-8.

245.Lanciano RM, Won M, Coia LR, Hanks GE. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. International journal of radiation oncology, biology, physics. 1991;20(4):667-76.

246.Dimopoulos JC, Lang S, Kirisits C, Fidarova EF, Berger D, Georg P, et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy. International journal of radiation oncology, biology, physics. 2009;75(1):56-63.

247.Thomas GM. Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. The New England journal of medicine. 1999;340(15):1198-200.

248.Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. The Cochrane database of systematic reviews. 2005(3):CD002225.

249.Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(35):5802-12.

250.Tanderup K, Eifel PJ, Yashar CM, Potter R, Grigsby PW. Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. International journal of radiation oncology, biology, physics. 2014;88(3):537-9.

251.Petereit DG, Frank SJ, Viswanathan AN, Erickson B, Eifel P, Nguyen PL, et al. Brachytherapy: where has it gone? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(9):980-2.

252.Lim K, Small W, Jr., Portelance L, Creutzberg C, Jurgenliemk-Schulz IM, Mundt A, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. International journal of radiation oncology, biology, physics. 2011;79(2):348-55.

253.Small W, Jr., Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. International journal of radiation oncology, biology, physics. 2008;71(2):428-34.

254.Taylor A, Rockall AG, Reznek RH, Powell ME. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. International journal of radiation oncology, biology, physics. 2005;63(5):1604-12.

255.Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby PW, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. Jama. 1995;274(5):387-93.

256.Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(5):872-80.

257.Liang JA, Chen SW, Hung YC, Yeh LS, Chang WC, Lin WC, et al. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(5):901-7.

258.Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, et al. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. International journal of radiation oncology, biology, physics. 2007;68(1):166-71.

259.Jensen LG, Hasselle MD, Rose BS, Nath SK, Hasan Y, Scanderbeg DJ, et al. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(1):119-25.

260.Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. International journal of radiation oncology, biology, physics. 1991;21(1):109-22.

261.Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. International journal of radiation oncology, biology, physics. 2010;76(3 Suppl):S3-9.

262.Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009;93(2):153-67.

263.Au SP, Grigsby PW. The irradiation tolerance dose of the proximal vagina. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2003;67(1):77-85.

264.Yang B, Zhu L, Cheng H, Li Q, Zhang Y, Zhao Y. Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis. Radiation oncology. 2012;7:197.

265.Lv Y, Wang F, Yang L, Sun G. Intensity-modulated whole pelvic radiotherapy provides effective dosimetric outcomes for cervical cancer treatment with lower toxicities. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2014;18(8):745-52.

266.Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, et al. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. International journal of radiation oncology, biology, physics. 2011;80(5):1436-45.

267.Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2005;74(3):235-45.

268.Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2006;78(1):67-77.

269.Hellebust TP, Kirisits C, Berger D, Perez-Calatayud J, De Brabandere M, De Leeuw A, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2010;96(2):153-60.

270.Dimopoulos JC, Petrow P, Tanderup K, Petric P, Berger D, Kirisits C, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012;103(1):113-22.

271.Nag S, Cardenes H, Chang S, Das IJ, Erickson B, Ibbott GS, et al. Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. International journal of radiation oncology, biology, physics. 2004;60(4):1160-72.

272.Viswanathan AN, Beriwal S, De Los Santos JF, Demanes DJ, Gaffney D, Hansen J, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012;11(1):47-52.

273.Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations C, American Brachytherapy S. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012;11(1):33-46.

274.Lee LJ, Das IJ, Higgins SA, Jhingran A, Small W, Jr., Thomadsen B, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Brachytherapy. 2012;11(1):53-7.

275.Potter R, Dimopoulos J, Georg P, Lang S, Waldhausl C, Wachter-Gerstner N, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2007;83(2):148-55.

276.Haie-Meder C, Chargari C, Rey A, Dumas I, Morice P, Magne N. MRI-based low dose-rate brachytherapy experience in locally advanced cervical cancer patients initially treated by concomitant chemoradiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2010;96(2):161-5.

277.Dimopoulos JC, Kirisits C, Petric P, Georg P, Lang S, Berger D, et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: clinical feasibility and preliminary results. International journal of radiation oncology, biology, physics. 2006;66(1):83-90.

278.Mohamed S, Kallehauge J, Fokdal L, Lindegaard JC, Tanderup K. Parametrial boosting in locally advanced cervical cancer: combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy. Brachytherapy. 2015;14(1):23-8.

279.Potter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;100(1):116-23.

280.Nesvacil N, Potter R, Sturdza A, Hegazy N, Federico M, Kirisits C. Adaptive image guided brachytherapy for cervical cancer: a combined MRI-/CT-planning technique with MRI only at first fraction. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;107(1):75-81.

281.Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. International journal of radiation oncology, biology, physics. 1995;32(5):1275-88.

282.Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1992;25(4):273-9.

283.Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. International journal of radiation oncology, biology, physics. 1993;25(3):391-7.

284.Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. International journal of radiation oncology, biology, physics. 2007;68(3):654-61.

285.Allgood JW, Langberg CW, Sung CC, Hauer-Jensen M. Timing of concomitant boost irradiation affects incidence and severity of intestinal complications. International journal of radiation oncology, biology, physics. 1996;34(2):381-7.

286.Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2007;84(1):5-10.

287.Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(3):555-63.

288.Kapp KS, Poschauko J, Geyer E, Berghold A, Oechs AC, Petru E, et al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. International journal of radiation oncology, biology, physics. 2002;54(1):58-66.

289.Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. International journal of radiation oncology, biology, physics. 2003;56(3):778-87.

290.Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86(8):1528-36.

291.Strauss HG, Haensgen G, Dunst J, Hayward CR, Burger HU, Scherhag A, et al. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(3):515-24.

292.Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecologic oncology. 2008;108(2):317-25.

293.Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma--a prospective study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012;103(1):38-44.

294.Pantarotto J, Malone S, Dahrouge S, Gallant V, Eapen L. Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy. BJU international. 2007;99(3):564-9.

295.Chen AM, Chen LM, Vaughan A, Sreeraman R, Farwell DG, Luu Q, et al. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. International journal of radiation oncology, biology, physics. 2011;79(2):414-9.

296.Alsadius D, Hedelin M, Johansson KA, Pettersson N, Wilderang U, Lundstedt D, et al. Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;101(3):495-501.

297.Jadon R, Pembroke CA, Hanna CL, Palaniappan N, Evans M, Cleves AE, et al. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clinical oncology. 2014;26(4):185-96.

298.Ahmad R, Hoogeman MS, Quint S, Mens JW, de Pree I, Heijmen BJ. Inter-fraction bladder filling variations and time trends for cervical cancer patients assessed with a portable 3-dimensional ultrasound bladder scanner. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;89(2):172-9.

299.Taylor A, Powell ME. An assessment of interfractional uterine and cervical motion: implications for radiotherapy target volume definition in gynaecological cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;88(2):250-7.

300.Stewart J, Lim K, Kelly V, Xie J, Brock KK, Moseley J, et al. Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer. International journal of radiation oncology, biology, physics. 2010;78(2):350-8.

301.Bondar ML, Hoogeman MS, Mens JW, Quint S, Ahmad R, Dhawtal G, et al. Individualized nonadaptive and online-adaptive intensity-modulated radiotherapy treatment strategies for cervical cancer patients based on pretreatment acquired variable bladder filling computed tomography scans. International journal of radiation oncology, biology, physics. 2012;83(5):1617-23.

302.Ahmad R, Bondar L, Voet P, Mens JW, Quint S, Dhawtal G, et al. A margin-of-the-day online adaptive intensity-modulated radiotherapy strategy for cervical cancer provides superior treatment accuracy compared to clinically recommended margins: a dosimetric evaluation. Acta oncologica. 2013;52(7):1430-6.

303.Lim K, Stewart J, Kelly V, Xie J, Brock KK, Moseley J, et al. Dosimetrically triggered adaptive intensity modulated radiation therapy for cervical cancer. International journal of radiation oncology, biology, physics. 2014;90(1):147-54.

304.Oh S, Stewart J, Moseley J, Kelly V, Lim K, Xie J, et al. Hybrid adaptive radiotherapy with on-line MRI in cervix cancer IMRT. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014;110(2):323-8.

305.Heijkoop ST, Langerak TR, Quint S, Bondar L, Mens JW, Heijmen BJ, et al. Clinical implementation of an online adaptive plan-of-the-day protocol for nonrigid motion management in locally advanced cervical cancer IMRT. International journal of radiation oncology, biology, physics. 2014;90(3):673-9.

306.Fuller AF, Jr., Elliott N, Kosloff C, Hoskins WJ, Lewis JL, Jr. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecologic oncology. 1989;33(1):34-9.

307.Kamura T, Tsukamoto N, Tsuruchi N, Saito T, Matsuyama T, Akazawa K, et al. Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy. Cancer. 1992;69(1):181-6.

308.Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. International journal of radiation oncology, biology, physics. 2006;65(1):169-76.

309.Bilek K, Ebeling K, Leitsmann H, Seidel G. Radical pelvic surgery versus radical surgery plus radiotherapy for stage Ib carcinoma of the cervix uteri. Preliminary results of a prospective randomized clinical study. Archiv fur Geschwulstforschung. 1982;52(3):223-9.

310.Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. The Cochrane database of systematic reviews. 2012;6:CD005342.

311.Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2003;68(3):217-26.

312.Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer treatment reviews. 2003;29(6):471-88.

313.Gondi V, Bentzen SM, Sklenar KL, Dunn EF, Petereit DG, Tannehill SP, et al. Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. International journal of radiation oncology, biology, physics. 2012;84(4):973-82.

314.Kirchheiner K, Nout RA, Tanderup K, Lindegaard JC, Westerveld H, Haie-Meder C, et al. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. International journal of radiation oncology, biology, physics. 2014;89(1):88-95.

315.Kinney WK, Alvarez RD, Reid GC, Schray MF, Soong SJ, Morley GW, et al. Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study. Gynecologic oncology. 1989;34(3):258-62.

316.Zhang G, Fu C, Zhang Y, Wang J, Qiao N, Yang Q, et al. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012;22(7):1220-5.

317.Saatli B, Olgan S, Gorken IB, Uslu T, Saygili U, Dicle N, et al. Tumor-free distance from outermost layer of cervix is of prognostic value in surgically treated cervical cancer patients: a multicenter study. Archives of gynecology and obstetrics. 2014;289(6):1331-5.

318.Lim CS, Alexander-Sefre F, Allam M, Singh N, Aleong JC, Al-Rawi H, et al. Clinical value of immunohistochemically detected lymphovascular space invasion in early stage cervical carcinoma. Annals of surgical oncology. 2008;15(9):2581-8.

319.Estape RE, Angioli R, Madrigal M, Janicek M, Gomez C, Penalver M, et al. Close vaginal margins as a prognostic factor after radical hysterectomy. Gynecologic oncology. 1998;68(3):229-32.

320.Zolciak-Siwinska A, Jonska-Gmyrek J. Glassy cell carcinoma of the cervix: a literature review. European journal of obstetrics, gynecology, and reproductive biology. 2014;179:232-5.

321.Guitarte C, Alagkiozidis I, Mize B, Stevens E, Salame G, Lee YC. Glassy cell carcinoma of the cervix: a systematic review and meta-analysis. Gynecologic oncology. 2014;133(2):186-91.

322.Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecologic oncology. 2010;116(1):44-9.

323.Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48(4):899-903.

324.Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(19):2129-35.

325.Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(15):3113-9.

326.Long HJ, 3rd, Bundy BN, Grendys EC, Jr., Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(21):4626-33.

327.Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(28):4649-55.

328.Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. The New England journal of medicine. 2014;370(8):734-43.

329.Phippen NT, Leath CA, 3rd, Havrilesky LJ, Barnett JC. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? Gynecologic oncology. 2015;136(1):43-7.

330.Cella D. Bevacizumab and quality of life in advanced cervical cancer. The Lancet Oncology. 2015;16(3):241-3.

331.Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecologic oncology. 2011;122(1):190-8.

332.Embry JR, Kelly MG, Post MD, Spillman MA. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy. Gynecologic oncology. 2011;120(3):444-8.

333.Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine [corrected] carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. The American journal of surgical pathology. 1997;21(8):905-14.

334.McCusker ME, Cote TR, Clegg LX, Tavassoli FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecologic oncology. 2003;88(3):333-9.

335.Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(7):2426-32.

336.Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecologic oncology. 2004;93(1):27-33.

337.Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(18):3495-501.

338.Chang TC, Lai CH, Tseng CJ, Hsueh S, Huang KG, Chou HH. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer. 1998;83(4):712-8.

339.Sevin BU, Method MW, Nadji M, Lu Y, Averette HA. Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer. 1996;77(8):1489-93.

340.Zivanovic O, Leitao MM, Jr., Park KJ, Zhao H, Diaz JP, Konner J, et al. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecologic oncology. 2009;112(3):590-3.

341.Morris M, Gershenson DM, Eifel P, Silva EG, Mitchell MF, Burke TW, et al. Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide. Gynecologic oncology. 1992;47(1):62-5.

342.Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. Journal of the American College of Cardiology. 2003;42(6):1037-43.

343.Chang TC, Hsueh S, Lai CH, Tseng CJ, Lee KF, Huang KG, et al. Phase II trial of neoadjuvant chemotherapy in early-stage small cell cervical cancer. Anti-cancer drugs. 1999;10(7):641-6.

344.Bermudez A, Vighi S, Garcia A, Sardi J. Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecologic oncology. 2001;82(1):32-9.

345.Sheets EE, Berman ML, Hrountas CK, Liao SY, DiSaia PJ. Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma. Obstetrics and gynecology. 1988;71(1):10-4.

346.O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(34):5441-7.

347.Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer. 1998;83(5):1033-40.

348.The National Board of Health and Welfare. 2012; Cancer Incidence in Sweden ISBN: 978-91-7555-126-5.

349.Cancer incidence in five continents. Volume IX. IARC scientific publications. 2008(160):1-837.

350.Gunderson CC, Nugent EK, Yunker AC, Rocconi RP, Graybill WS, Erickson BK, et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. Journal of lower genital tract disease. 2013;17(4):409-13.

351.Henson D, Tarone R. An epidemiologic study of cancer of the cervix, vagina, and vulva based on the Third National Cancer Survey in the United States. American journal of obstetrics and gynecology. 1977;129(5):525-32.

352.Pukkala E, Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995). International journal of cancer Journal international du cancer. 1999;81(1):56-61.

353.Hildesheim A, Han C-L, Brinton LA, Nasca PC, Richarts RM, Jones RB et al. Sexually transmitted agents and risk of carcinoma of the vagina. International Journal of Gynecological Cancer 1997;7:251-5. ISSN: 1048-891X.

354.Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecologic oncology. 2002;84(2):263-70.

355.Brinton LA, Nasca PC, Mallin K, Schairer C, Rosenthal J, Rothenberg R, et al. Case-control study of in situ and invasive carcinoma of the vagina. Gynecologic oncology. 1990;38(1):49-54.

356.De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. International journal of cancer Journal international du cancer. 2009;124(7):1626-36.

357.Alemany L, Saunier M, Tinoco L, Quiros B, Alvarado-Cabrero I, Alejo M, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. European journal of cancer. 2014;50(16):2846-54.

358.Gadducci A, Fabrini MG, Lanfredini N, Sergiampietri C. Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. Critical reviews in oncology/hematology. 2015;93(3):211-24.

359.Indraccolo U, Chiocci L, Baldoni A. Does vaginal intraepithelial neoplasia have the same evolution as cervical intraepithelial neoplasia? European journal of gynaecological oncology. 2008;29(4):371-3.

360.Wharton JT, Tortolero-Luna G, Linares AC, Malpica A, Baker VV, Cook E, et al. Vaginal intraepithelial neoplasia and vaginal cancer. Obstet Gynecol Clin North Am. 1996;23(2):325-45.

361.Newman W, Cromer JK. The multicentric origin of carcinomas of the female anogenital tract. Surgery, gynecology & obstetrics. 1959;108(3):273-81.

362.Chyle V, Zagars GK, Wheeler JA, Wharton JT, Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. International journal of radiation oncology, biology, physics. 1996;35(5):891-905.

363.Hellman K, Silfversward C, Nilsson B, Hellstrom AC, Frankendal B, Pettersson F. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956-96. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2004;14(3):491-501.

364.Schockaert S, Poppe W, Arbyn M, Verguts T, Verguts J. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. American journal of obstetrics and gynecology. 2008;199(2):113 e1-5.

365.Herman JM, Homesley HD, Dignan MB. Is hysterectomy a risk factor for vaginal cancer? Jama. 1986;256(5):601-3.

366.Li Z, Barron S, Hong W, Karunamurthy A, Zhao C. Surveillance for recurrent cancers and vaginal epithelial lesions in patients with invasive cervical cancer after hysterectomy: are vaginal cytology and high-risk human papillomavirus testing useful? American journal of clinical pathology. 2013;140(5):708-14.

367.Shah CA, Goff BA, Lowe K, Peters WA, 3rd, Li CI. Factors affecting risk of mortality in women with vaginal cancer. Obstetrics and gynecology. 2009;113(5):1038-45.

368.Jang WI, Wu HG, Ha SW, Kim HJ, Kang SB, Song YS, et al. Definitive radiotherapy for treatment of primary vaginal cancer: effectiveness and prognostic factors. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012;22(3):521-7.

369.Hiniker SM, Roux A, Murphy JD, Harris JP, Tran PT, Kapp DS, et al. Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes. Gynecologic oncology. 2013;131(2):380-5.

370.Hellman K, Lundell M, Silfversward C, Nilsson B, Hellstrom AC, Frankendal B. Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16(3):1201-11.

371.Hacker NF, Eifel PJ, van der Velden J. Cancer of the vagina. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2012;119 Suppl 2:S97-9.

372.Pingley S, Shrivastava SK, Sarin R, Agarwal JP, Laskar S, Deshpande DD, et al. Primary carcinoma of the vagina: Tata Memorial Hospital experience. International journal of radiation oncology, biology, physics. 2000;46(1):101-8.

373.Hellman K, Frankendal B. Molecular markers of malignant tumours of the vagina. In CME Journal of Gynecologic Oncology. Syrjänen KJ. Budapest: NOK Press 2006-11, 1, pp 23-29.

374.Brunner AH, Grimm C, Polterauer S, Hefler L, Stani J, Heinze G, et al. The prognostic role of human papillomavirus in patients with vaginal cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(5):923-9.

375.Alonso I, Felix A, Torne A, Fuste V, del Pino M, Castillo P, et al. Human papillomavirus as a favorable prognostic biomarker in squamous cell carcinomas of the vagina. Gynecologic oncology. 2012;125(1):194-9.

376.Larsson GL, Helenius G, Andersson S, Sorbe B, Karlsson MG. Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma. Gynecologic oncology. 2013;129(2):406-11.

377.Hellman K, Lindquist D, Ranhem C, Wilander E, Andersson S. Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina. British journal of cancer. 2014;110(6):1561-70.

378.Feldbaum VM, Flowers LC, Oprea-Ilies GM. Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. American journal of clinical pathology. 2014;142(5):664-9.

379.Hellman K, Alaiya AA, Becker S, Lomnytska M, Schedvins K, Steinberg W, et al. Differential tissue-specific protein markers of vaginal carcinoma. British journal of cancer. 2009;100(8):1303-14.

380.Pride GL, Buchler DA. Carcinoma of vagina 10 or more years following pelvic irradiation therapy. American journal of obstetrics and gynecology. 1977;127(5):513-7.

381.Perez CA, Grigsby PW, Garipagaoglu M, Mutch DG, Lockett MA. Factors affecting long-term outcome of irradiation in carcinoma of the vagina. International journal of radiation oncology, biology, physics. 1999;44(1):37-45.

382.Davis KP, Stanhope CR, Garton GR, Atkinson EJ, O'Brien PC. Invasive vaginal carcinoma: analysis of early-stage disease. Gynecologic oncology. 1991;42(2):131-6.

383.Al-Kurdi M, Monaghan JM. Thirty-two years experience in management of primary tumours of the vagina. British journal of obstetrics and gynaecology. 1981;88(11):1145-50.

384.Stock RG, Chen AS, Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecologic oncology. 1995;56(1):45-52.

385.Houghton CR, Iversen T. Squamous cell carcinoma of the vagina: a clinical study of the location of the tumor. Gynecologic oncology. 1982;13(3):365-72.

386.Kirkbride P, Fyles A, Rawlings GA, Manchul L, Levin W, Murphy KJ, et al. Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989). Gynecologic oncology. 1995;56(3):435-43.

387.Griffin N, Grant LA, Sala E. Magnetic resonance imaging of vaginal and vulval pathology. European radiology. 2008;18(6):1269-80.

388.Lamoreaux WT, Grigsby PW, Dehdashti F, Zoberi I, Powell MA, Gibb RK, et al. FDG-PET evaluation of vaginal carcinoma. International journal of radiation oncology, biology, physics. 2005;62(3):733-7.

389.Hertel H, Soergel P, Muecke J, Schneider M, Papendorf F, Laenger F, et al. Is there a place for sentinel technique in treatment of vaginal cancer?: feasibility, clinical experience, and results. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(9):1692-8.

390.Rajagopalan MS, Xu KM, Lin JF, Sukumvanich P, Krivak TC, Beriwal S. Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecologic oncology. 2014;135(3):495-502.

391.Di Donato V, Bellati F, Fischetti M, Plotti F, Perniola G, Panici PB. Vaginal cancer. Critical reviews in oncology/hematology. 2012;81(3):286-95.

392.National Cancer Institute Guidelines 2015, www.cancer.gov.

393.Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. International journal of radiation oncology, biology, physics. 2005;62(1):138-47.

394.Kucera H, Langer M, Smekal G, Weghaupt K. Radiotherapy of primary carcinoma of the vagina: management and results of different therapy schemes. Gynecologic oncology. 1985;21(1):87-93.

395.Urbanski K, Kojs Z, Reinfuss M, Fabisiak W. Primary invasive vaginal carcinoma treated with radiotherapy: analysis of prognostic factors. Gynecologic oncology. 1996;60(1):16-21.

396.Grigsby PW. Vaginal cancer. Current treatment options in oncology. 2002;3(2):125-30.

397.de Crevoisier R, Sanfilippo N, Gerbaulet A, Morice P, Pomel C, Castaigne D, et al. Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2007;85(3):362-70.

398.Tjalma WA, Monaghan JM, de Barros Lopes A, Naik R, Nordin AJ, Weyler JJ. The role of surgery in invasive squamous carcinoma of the vagina. Gynecologic oncology. 2001;81(3):360-5.

399.Lee WR, Marcus RB, Jr., Sombeck MD, Mendenhall WM, Morgan LS, Freeman DE, et al. Radiotherapy alone for carcinoma of the vagina: the importance of overall treatment time. International journal of radiation oncology, biology, physics. 1994;29(5):983-8.

400.Thigpen JT, Blessing JA, Homesley HD, Berek JS, Creasman WT. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecologic oncology. 1986;23(1):101-4.

401.Benedetti Panici P, Bellati F, Plotti F, Di Donato V, Antonilli M, Perniola G, et al. Neoadjuvant chemotherapy followed by radical surgery in patients affected by vaginal carcinoma. Gynecologic oncology. 2008;111(2):307-11.

402.Lv L, Sun Y, Liu H, Lou J, Peng Z. Neoadjuvant chemotherapy followed by radical surgery and reconstruction of the vagina in a patient with stage II primary vaginal squamous carcinoma. The journal of obstetrics and gynaecology research. 2010;36(6):1245-8.

403.Miyamoto DT, Viswanathan AN. Concurrent chemoradiation for vaginal cancer. PloS one. 2013;8(6):e65048.

404.Samant R, Lau B, E C, Le T, Tam T. Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. International journal of radiation oncology, biology, physics. 2007;69(3):746-50.

405.Dalrymple JL, Russell AH, Lee SW, Scudder SA, Leiserowitz GS, Kinney WK, et al. Chemoradiation for primary invasive squamous carcinoma of the vagina. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2004;14(1):110-7.

406.Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. Journal of the National Cancer Institute. 2008;100(23):1707-16.

407.Hintz BL, Kagan AR, Chan P, Gilbert HA, Nussbaum H, Rao AR, et al. Radiation tolerance of the vaginal mucosa. International journal of radiation oncology, biology, physics. 1980;6(6):711-6.

408.Kaidar-Person O, Abdah-Bortnyak R, Amit A, Nevelsky A, Berniger A, Bar-Deroma R, et al. Tolerance of the vaginal vault to high-dose rate brachytherapy and concomitant chemo-pelvic irradiation: Long-term perspective. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. 2014;19(1):56-61.

409.Nevelsky A, Bar-Deroma R, Cokal GY, Rosenblatt E, Kuten A. Definition of vaginal doses in intrauterine high-dose-rate brachytherapy. Brachytherapy. 2004;3(2):101-5.

410.Blecharz P, Reinfuss M, Jakubowicz J, Skotnicki P, Walasek T, Luczynska E. Effectiveness of radiotherapy in patients with primary invasive vaginal carcinoma. European journal of gynaecological oncology. 2013;34(5):436-41.

411.Jager L, Nilsson PJ, Radestad AF. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(4):755-62.

412.Benn T, Brooks RA, Zhang Q, Powell MA, Thaker PH, Mutch DG, et al. Pelvic exenteration in gynecologic oncology: a single institution study over 20 years. Gynecologic oncology. 2011;122(1):14-8.

413.Baiocchi G, Guimaraes GC, Faloppa CC, Kumagai LY, Oliveira RA, Begnami MD, et al. Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? Annals of surgical oncology. 2013;20(5):1694-700.

414.Pettersson BF, Andersson S, Hellman K, Hellstrom AC. Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience. Cancer. 2010;116(10):2343-9.

415.Amant F, Halaska MJ, Fumagalli M, Dahl Steffensen K, Lok C, Van Calsteren K, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(3):394-403.

416.Alouini S, Rida K, Mathevet P. Cervical cancer complicating pregnancy: implications of laparoscopic lymphadenectomy. Gynecologic oncology. 2008;108(3):472-7.

417.Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. The Lancet Oncology. 2012;13(3):256-64.

418.Keulers BJ, Scheltinga MR, Houterman S, Van Der Wilt GJ, Spauwen PH. Surgeons underestimate their patients' desire for preoperative information. World journal of surgery. 2008;32(6):964-70.

419.Lithner, M. and T. Zilling, Does preoperative information increase the wellbeing of the patient after surgery? (in Swedish). Vård i Norden 1998; 18:31-33,39.

420.Burney M, Purden M, McVey L. Patient satisfaction and nurses' perceptions of quality in an inpatient cardiology population. Journal of nursing care quality. 2002;16(4):56-67; quiz 8-9.

421.Jones KR, Burney RE, Christy B. Patient expectations for surgery: are they being met? The Joint Commission journal on quality improvement. 2000;26(6):349-60.

422.Wiggins DL, Wood R, Granai CO, Dizon DS. Sex, intimacy, and the gynecologic oncologists: survey results of the New England Association of Gynecologic Oncologists (NEAGO). Journal of psychosocial oncology. 2007;25(4):61-70.

423.Cullen K, Fergus K, Dasgupta T, Fitch M, Doyle C, Adams L. From "sex toy" to intrusive imposition: a qualitative examination of women's experiences with vaginal dilator use following treatment for gynecological cancer. The journal of sexual medicine. 2012;9(4):1162-73.

424.Annon JS, The PLISSIT model: A proposed conceptual scheme for the behavioral treatment of sexual problems. J Sex Edu Ther 1976;2:1-15.

425.Carter J, Chi DS, Brown CL, Abu-Rustum NR, Sonoda Y, Aghajanian C, et al. Cancer-related infertility in survivorship. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(1):2-8.

426.Armuand GM, Rodriguez-Wallberg KA, Wettergren L, Ahlgren J, Enblad G, Hoglund M, et al. Sex differences in fertility-related information received by young adult cancer survivors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2147-53.

427.Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. Cancer. 2015;121(10):1532-9.

428.de Hullu JA, Pras E, Hollema H, van der Zee AG, Bogchelman DH, Mourits MJ. Presentations of endometrial activity after curative radiotherapy for cervical cancer. Maturitas. 2005;51(2):172-6.

429.van der Stege JG, Groen H, van Zadelhoff SJ, Lambalk CB, Braat DD, van Kasteren YM, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008;15(1):23-31.

430.Everhov AH, Floter Radestad A, Nyberg T, Smedby KE, Bergmark K, Linden Hirschberg A. Serum Androgen Levels and Sexual Function Before and One Year After Treatment of Uterine Cervical Cancer: A Pilot Study. The journal of sexual medicine. 2016;13(3):413-24.

431.Moller MC, Radestad AF, von Schoultz B, Bartfai A. Effect of estrogen and testosterone replacement therapy on cognitive fatigue. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013;29(2):173-6.

432.Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause international. 2010;16(2):89-93.

433.MacLennan AH. HRT in difficult circumstances: are there any absolute contraindications? Climacteric : the journal of the International Menopause Society. 2011;14(4):409-17.

434.Hellbom, M och Thomé, B. s 210 ff, kapitel 12, Mötet kring existentiella frågor. I Rehabilitering vid cancersjukdom. Att möta framtiden. Stockholm, Natur och Kultur 2013.

435.Leonhardt H, Mellander S, Snygg J, Lonn L. Endovascular management of acute bleeding arterioenteric fistulas. Cardiovascular and interventional radiology. 2008;31(3):542-9.

436.Vistad I, Kristensen GB, Fossa SD, Dahl AA, Morkrid L. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. International journal of radiation oncology, biology, physics. 2009;73(4):1141-7.

437.Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta obstetricia et gynecologica Scandinavica. 2002;81(5):443-50.

438.Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, et al. Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecologic oncology. 2012;124(3):389-94.

439.Dunberger G, Lindquist H, Waldenstrom AC, Nyberg T, Steineck G, Avall-Lundqvist E. Lower limb lymphedema in gynecological cancer survivors--effect on daily life functioning. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013;21(11):3063-70.

440.Beesley V, Janda M, Eakin E, Obermair A, Battistutta D. Lymphedema after gynecological cancer treatment : prevalence, correlates, and supportive care needs. Cancer. 2007;109(12):2607-14.

441.Sekse RJ, Raaheim M, Blaaka G, Gjengedal E. Life beyond cancer: women's experiences 5 years after treatment for gynaecological cancer. Scandinavian journal of caring sciences. 2010;24(4):799-807.

442.Bergmark K, Avall-Lundqvist E, Dickman PW, Steineck G, Henningsohn L. Synergy between sexual abuse and cervical cancer in causing sexual dysfunction. Journal of sex & marital therapy. 2005;31(5):361-83.

443.Coker AL, Hopenhayn C, DeSimone CP, Bush HM, Crofford L. Violence against Women Raises Risk of Cervical Cancer. Journal of women's health. 2009;18(8):1179-85.

444.Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. American journal of obstetrics and gynecology. 2011;204(6):466-78.

445.Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M, Gynecology Cancer Disease Site G. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecologic oncology. 2009;114(3):528-35.

446.Shield PW, Wright RG, Free K, Daunter B. The accuracy of cervicovaginal cytology in the detection of recurrent cervical carcinoma following radiotherapy. Gynecologic oncology. 1991;41(3):223-9.

447.Lanowska M, Mangler M, Grittner U, Akbar GR, Speiser D, von Tucher E, et al. Isthmic-vaginal smear cytology in the follow-up after radical vaginal trachelectomy for early stage cervical cancer: is it safe? Cancer cytopathology. 2014;122(5):349-58.

448.Sartori E, Pasinetti B, Carrara L, Gambino A, Odicino F, Pecorelli S. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecologic oncology. 2007;107(1 Suppl 1):S241-7.

449.Lanceley A, Fiander A, McCormack M, Bryant A. Follow-up protocols for women with cervical cancer after primary treatment. The Cochrane database of systematic reviews. 2013;11:CD008767.

450.Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecologic oncology. 2000;78(2):187-93.

451.Zola P, Fuso L, Mazzola S, Piovano E, Perotto S, Gadducci A, et al. Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. Gynecologic oncology. 2007;107(1 Suppl 1):S150-4.

452.Morice P, Deyrolle C, Rey A, Atallah D, Pautier P, Camatte S, et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004;15(2):218-23.

453.Duyn A, Van Eijkeren M, Kenter G, Zwinderman K, Ansink A. Recurrent cervical cancer: detection and prognosis. Acta obstetricia et gynecologica Scandinavica. 2002;81(8):759-63.

454.Kew FM, Galaal K, Manderville H. Patients' views of follow-up after treatment for gynaecological cancer. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2009;29(2):135-42.

455.Olaitan A, Murdoch J, Anderson R, James J, Graham J, Barley V. A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001;11(5):349-53.

456.Kerr-Wilson RH, McCrum A. Follow-up of patients with gynaecological cancer. The Australian & New Zealand journal of obstetrics & gynaecology. 1995;35(3):298-9.

457.Dahl L, Wittrup I, Petersen LK, Blaakaer J, Vaeggemose U. Paradoxes of follow-up - health professionals' views on follow-up after surgical treatment in gynecological cancer. Acta oncologica. 2015;54(2):194-9.

458.Dunberger G, Bergmark K. Nurse-led care for the management of side effects of pelvic radiotherapy: what does it achieve? Current opinion in supportive and palliative care. 2012;6(1):60-8.

459.Benton B, Norton C, Lindsay JO, Dolan S, Andreyev HJ. Can nurses manage gastrointestinal symptoms arising from pelvic radiation disease? Clinical oncology. 2011;23(8):538-51.

460.Donati OF, Lakhman Y, Sala E, Burger IA, Vargas HA, Goldman DA, et al. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration. European radiology. 2013;23(10):2906-15.

461.Testa AC, Di Legge A, Virgilio B, Bonatti M, Manfredi R, Mirk P, et al. Which imaging technique should we use in the follow up of gynaecological cancer? Best practice & research Clinical obstetrics & gynaecology. 2014;28(5):769-91.

462.Friedlander M, Grogan M, Force USPST. Guidelines for the treatment of recurrent and metastatic cervical cancer. The oncologist. 2002;7(4):342-7.

463.Ang C, Bryant A, Barton DP, Pomel C, Naik R. Exenterative surgery for recurrent gynaecological malignancies. The Cochrane database of systematic reviews. 2014;2:CD010449.

464.Sharma S, Odunsi K, Driscoll D, Lele S. Pelvic exenterations for gynecological malignancies: twenty-year experience at Roswell Park Cancer Institute. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2005;15(3):475-82.

465.Shafer A, Boggess JF. Robotic-assisted endometrial cancer staging and radical hysterectomy with the da Vinci surgical system. Gynecologic oncology. 2008;111(2 Suppl):S18-23.

466.Diver EJ, Rauh-Hain JA, Del Carmen MG. Total pelvic exenteration for gynecologic malignancies. International journal of surgical oncology. 2012;2012:693535.

467.Maggioni A, Roviglione G, Landoni F, Zanagnolo V, Peiretti M, Colombo N, et al. Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. Gynecologic oncology. 2009;114(1):64-8.

468.Stanhope CR, Webb MJ, Podratz KC. Pelvic exenteration for recurrent cervical cancer. Clinical obstetrics and gynecology. 1990;33(4):897-909.

469.Magrina JF, Stanhope CR, Weaver AL. Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecologic oncology. 1997;64(1):130-5.

470.van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;98(3):287-91.

471.Kim DH, Lee JH, Ki YK, Nam JH, Kim WT, Jeon HS, et al. Short-course palliative radiotherapy for uterine cervical cancer. Radiation oncology journal. 2013;31(4):216-21.

472.Josephs SC. Obstetric and gynecologic emergencies: a review of indications and interventional techniques. Seminars in interventional radiology. 2008;25(4):337-46.

473.Yalvac S, Kayikcioglu F, Boran N, Tulunay G, Kose MF, Bilgic S, et al. Embolization of uterine artery in terminal stage cervical cancers. Cancer investigation. 2002;20(5-6):754-8.

474.Howell DD, James JL, Hartsell WF, Suntharalingam M, Machtay M, Suh JH, et al. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14. Cancer. 2013;119(4):888-96.

475.Oguntayo O, Zayyan M, Kolawole A, Adewuyi S, Ismail H, Koledade K. Cancer of the cervix in Zaria, Northern Nigeria. Ecancermedicalscience. 2011;5:219.

476.Hope JM, Pothuri B. The role of palliative surgery in gynecologic cancer cases. The oncologist. 2013;18(1):73-9.

477.Lopez-Acevedo M, Lowery WJ, Lowery AW, Lee PS, Havrilesky LJ. Palliative and hospice care in gynecologic cancer: a review. Gynecologic oncology. 2013;131(1):215-21.

478.Dean A. The palliative effects of octreotide in cancer patients. Chemotherapy. 2001;47 Suppl 2:54-61.

479.Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecologic oncology. 2007;107(1):99-106.

480.Verleye L, Vergote I, Reed N, Ottevanger PB. Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009;20(10):1631-8.

481.Andreyev HJ, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, et al. Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet. 2013;382(9910):2084-92.